8legs: Eli lilly and company

Your Followed Topics

#1 out of 3

health18h ago

Eli Lilly said it would unpause UK investments if ministers agree to regular NHS price increases and end the rebate scheme.
Patrik Jonsson said talks with UK ministers are ongoing and a summer agreement could be reached.
Lilly paused about £25bn of UK investments last year, including a London laboratory site.
The company is exploring innovative pricing models, including outcome-based agreements tied to work-related benefits.
The UK government says changes to medicine pricing will help thousands gain faster access to new treatments.
The US-UK pharmaceutical pricing deal includes raising the NICE cost-effectiveness threshold.
Lilly expects a pill version of Mounjaro to launch later this year.
Keir Starmer’s government has previously agreed to higher NHS price thresholds for medicines.
The government insists it remains committed to the US-UK pharmaceutical agreement and pricing reforms.
Industry groups expect the rebate scheme to fall, potentially reducing refunds over time.

Vote 0

#2 out of 3

MeiraGTx reports 2025 revenue of $81.4 million, up from 2024, driven largely by a $75 million upfront license from Lilly.
Net loss for 2025 narrowed to $(114.2) million as operating losses decreased and license revenue contributed to results.
Strategic collaborations include Lilly and Hologen, with Lilly providing a $75 million upfront and Hologen funding $200 million for a joint venture.
FDA Breakthrough and RMAT designations were awarded for AAV2-hAQP1, with RMAT for AAV-GAD and progression toward Phase 3.
Manufacturing capacity includes two GMP viral vector facilities and a Johnson & Johnson supply agreement for bot-a-vec.
Riboswitch platform advances toward a clinical Ribo-leptin program and broadens indications to trigeminal neuralgia.
Company highlighted two GMP facilities and in-house production as part of its manufacturing and supply capabilities.
The 2025 results reflect licensing revenue and changes in service revenue contributing to profitability improvements.
Total operating expenses were $187.4 million in 2025, influencing the operating loss outcome.
The 2025 results include a $4.8 million related party cost within revenue recognition.

Vote 0

#3 out of 3

U.S. stock futures rose as investors anticipated a material rebound after a challenging previous week.
Oil prices climbed on reports of policy moves and ongoing tensions in the Middle East.
The market faces near-term oil dynamics that could influence inflation and borrowing costs.
Trump signaled progress in talks with Iran, fueling renewed market optimism.
The report notes leadership changes and potential policy impacts on energy and finance sectors.
TSA funding and government-shutdown-related issues were addressed as part of broader market context.
Meta and AI-related legal developments were highlighted as potentially shaping tech valuations.
Eli Lilly and Insilico deal underscores AI's growing role in drug development and market potential.
Pokémon card market activity drew investor attention amid broader asset price trends.
The Daily Dividend outlines key events to watch this trading week, including earnings and payroll data.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.